Logo for Alpine Immune Sciences Inc

Alpine Immune Sciences Investor Relations Material

Latest events

Logo for Alpine Immune Sciences Inc

Study Update

Alpine Immune Sciences
Logo for Alpine Immune Sciences

Study Update

10 Apr, 2024
Logo for Alpine Immune Sciences

Q4 2023

18 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Alpine Immune Sciences Inc

Access all reports
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. The Company's lead product candidate, ALP-001 (Tocagen's AGS-003), an ADCC-enhancing therapeutic candidate for EGFRvIII+ glioma patients, is being developed in collaboration with Tocagen Inc., under an exclusive license from Transgene S.A.